Somatostatin

Overview

Somatostatin is a naturally occurring peptide hormone with powerful inhibitory effects on multiple hormonal and digestive functions. Discovered in the hypothalamus in 1973, it exists in two biologically active forms – Somatostatin-14 (SST-14) and Somatostatin-28 (SST-28)—both essential for regulating endocrine and gastrointestinal activity.

It is produced in several tissues:

1. Hypothalamus – inhibits growth hormone release
2. Pancreatic delta cells – regulate insulin and glucagon
3. Gastrointestinal tract – modulates digestive hormone secretion

It prevents the release of insulin, glucagon, gastrin, pancreatic enzymes, and suppresses growth hormone (GH), TSH, and prolactin from the pituitary. In the CNS, somatostatin influences neurotransmission and memory formation.

It acts by binding to G-protein-coupled receptors, reducing intracellular cAMP, decreasing calcium entry, and increasing potassium currents—ultimately suppressing hormone secretion and exerting anti-proliferative and cytostatic effects.

Due to its extremely short half-life (1–3 minutes), clinical evaluation of it requires testing Somatostatin-Like Immunoreactivity (SLI) in blood.

Symptoms

It imbalances—especially elevated levels—produce symptoms largely associated with somatostatinoma, an extremely rare neuroendocrine tumor. Symptoms result from the hormone’s powerful inhibitory effects.

Symptoms Associated with High Somatostatin Levels:

1. Refractory diarrhea due to impaired intestinal motility
2. Hypoglycemia from suppressed glucagon and insulin regulation
3. Steatorrhea and poor digestion due to decreased pancreatic enzymes
4. Gallbladder dysfunction and gallstones (due to reduced cholecystokinin activity)
5. Weight loss from malabsorption
6. Gastric acid reduction causes digestive discomfort

Since increased levels are strongly linked with GIT and pancreatic tumors, symptoms may also overlap with other endocrine or gastrointestinal disorders—making diagnosis challenging.

Causes

The primary cause of elevated levels is related to rare neuroendocrine tumors or genetic tumor syndromes.

Major Causes Include:

1. Somatostatinoma

1. A rare endocrine tumor of the pancreas or gastrointestinal tract.
2. Markedly increases these levels, leading to characteristic inhibitory symptoms.

2. Multiple Endocrine Neoplasia (MEN)

1. A hereditary disorder causing multiple neoplastic lesions in endocrine organs.
2. These lesions can elevate production of it or stimulate tumor formation in the pancreas/GIT.

3. Neurofibromatosis Type 1 (NF1)

1. A genetic disorder associated with endocrine abnormalities and tumor growth.
2. Can induce neoplasms that raise levels.

4. Von Hippel–Lindau Disease

1. A syndrome leading to benign or malignant tumors in multiple organs, including the pancreas.
2. Tumors in these regions contribute to excess levels.

5. Dietary and Physiological Stimuli

The secretion is triggered by:

1. Increased glucose, amino acids, fatty acids
2. Elevated GI hormones

It is inhibited by:

1. Acetylcholine
2. Low nutrient availability

Risk Factors

Individuals with certain genetic disorders or endocrine abnormalities are at higher risk of developing somatostatin excess.

Major Risk Factors:

1. Genetic Tumor Syndromes
   1. MEN
   2. NF1V
   3. on Hippel-Lindau disease
   4. These conditions predispose individuals to endocrine and pancreatic tumors.
2. Neuroendocrine Tumors
   1. Tumors of the pancreas or GI tract increase somatostatin levels.
3. Pancreatic Abnormalities
   1. Structural or functional disorders may trigger abnormal hormone secretion.
4. Increased Nutrient Load
   1. High levels of glucose, amino acids, or fatty acids may stimulate somatostatin release.

Because signs often overlap with other gastrointestinal or metabolic disorders, patients with these risk factors often require specific hormonal testing.

Prevention

Preventing abnormal somatostatin levels is primarily focused on early diagnosis, genetic awareness, and appropriate hormonal testing, since these disorders themselves are rare.

Testing-Based Prevention:

1. Measure Somatostatin-Like Immunoreactivity (SLI) in suspected cases.
2. Use a 10 mL blood sample in a tube containing GI preservative (T125).
3. Separate the specimen immediately and freeze 3 mL of plasma as soon as possible.
4. Expected normal SLI levels: 2.9 – 22.0 pg/mL.
5. Persistent high levels require evaluation for somatostatinoma or associated syndromes.

Clinical Prevention:

1. Monitor individuals with MEN, NF1, or VHL for endocrine tumor growth.
2. Evaluate unexplained diarrhea, hypoglycemia, or recurrent digestive symptoms early.
3. Routine follow-up for patients with neuroendocrine tumors.

Lifestyle & Supportive Prevention:

While lifestyle does not directly regulate somatostatin, maintaining good metabolic health supports better endocrine balance:

1. Balanced nutrient intake
2. Avoiding excessive fatty meals
3. Managing glucose levels
4. Timely medical evaluation for persistent GI or metabolic complaints